ImmuCell (NASDAQ:ICCC) Stock Price Breaks Above 200 Day Moving Average - Here's Why

Key Points

• ImmuCell shares broke above their 200-day moving average, reaching $10.37 before closing at $10.25, compared with the 200-day average of $9.77.
• The company reported a quarterly earnings beat, with EPS of $0.20 versus the $0.05 consensus and revenue of $7.19 million versus expectations of $5.40 million.
• Analyst sentiment remains mixed: Weiss Ratings upgraded the stock to “hold,” Wall Street Zen rated it a “strong buy,” while the overall MarketBeat consensus is “Hold.” Dimensional Fund Advisors also increased its stake by 3.2%.

ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) shares passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $9.77 and traded as high as $10.37. ImmuCell shares last traded at $10.25, with a volume of 11,335 shares trading hands.

Wall Street Analysts Forecast Growth

ICCC has been the topic of several recent research reports. Weiss Ratings raised ImmuCell from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday. Wall Street Zen upgraded ImmuCell to a "strong-buy" rating in a report on Saturday, June 27th. One investment analyst has rated the stock with a Hold rating. According to data from MarketBeat, ImmuCell currently has an average rating of "Hold".

ImmuCell Stock Down 1.8%

The stock's 50 day simple moving average is $10.00 and its two-hundred day simple moving average is $9.77. The firm has a market cap of $93.07 million, a P/E ratio of 128.14 and a beta of 0.56. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.75 and a quick ratio of 2.71.

ImmuCell (NASDAQ:ICCC - Get Free Report) last released its earnings results on Thursday, August 13th. The biotechnology company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.05 by $0.15. The business had revenue of $7.19 million for the quarter, compared to the consensus estimate of $5.40 million. ImmuCell had a return on equity of 2.69% and a net margin of 2.57%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in ImmuCell stock. Dimensional Fund Advisors LP grew its holdings in shares of ImmuCell Corporation (NASDAQ:ICCC - Free Report) by 3.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 56,030 shares of the biotechnology company's stock after purchasing an additional 1,749 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.62% of ImmuCell worth $355,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 13.47% of the company's stock.

ImmuCell Company Profile

ImmuCell Corporation NASDAQ: ICCC is a biotechnology company focused on developing and commercializing products that support the health and productivity of dairy and beef cattle. The company uses antibody-based and other biological technologies to address common livestock diseases and conditions, with an emphasis on products that can be administered conveniently on farms.

ImmuCell's primary commercial product is the First Defense line, which is designed to help protect newborn calves from bovine neonatal diarrhea, a condition associated with pathogens including rotavirus, coronavirus and Escherichia coli.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.